Elubrixin is primarily investigated for its potential in treating neurodegenerative disorders, particularly Alzheimer’s disease. It functions by modulating key pathways involved in neuronal survival and synaptic plasticity, helping to protect brain cells from damage caused by amyloid-beta toxicity. Its application extends to improving cognitive function in preclinical models, showing promise as a neuroprotective agent. Additionally, Elubrixin has been explored for its anti-inflammatory effects in the central nervous system, which may contribute to slowing disease progression. Ongoing research is evaluating its efficacy in combination therapies and its potential use in other conditions involving cognitive impairment or neuronal damage.